The text starts here.

News Release

FOR IMMEDIATE RELEASE
May 14, 2015

EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY PRODUCTS AND PIPELINE AT 51ST ASCO ANNUAL MEETING
HIGHLIGHTS INCLUDE NEW CLINICAL DATA ON HALAVEN® (ERIBULIN) IN SOFT TISSUE SARCOMA AND ON LENVIMA® (LENVATINIB) IN RENAL CELL CARCINOMA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that a series of abstracts highlighting new study results on Halaven® (eribulin mesylate; halichondrin class microtubule dynamics inhibitor, “eribulin”) and Lenvima® (lenvatinib mesylate; selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, “lenvatinib”) will be presented during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from May 29 to June 2, 2015.

The main presentations for this year's ASCO meeting include an oral presentation highlighting the results of a Phase III clinical study (Study 309) of eribulin in soft tissue sarcoma to be given on Monday, June 1. Furthermore, these findings have been chosen by ASCO to be featured in a press conference as part of the official press program starting at 10:30 a.m. (CDT) on Saturday, May 30.
For lenvatinib, an oral presentation on the results of a Phase II clinical study (Study 205) of the agent in metastatic renal cell carcinoma will also be given on Monday, June 1.
In addition, the poster sessions include a presentation of the results of an analysis concerning biomarkers of response and resistance in the Phase III study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT study).

Eisai positions oncology as a key franchise area. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, and in doing so seeks to make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families as well as healthcare providers.

Oral Presentations:
ProductAbstract title and scheduled presentation date and time (local time)
Eribulin
(Halaven®)

Abstract No: LBA10502
Randomized, open-label, multicenter, phase 3 study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI)

Oral Presentation | June 1 (Mon), 15:48-16:00
Lenvatinib
(Lenvima®)

Abstract No: 4506
Randomized phase 2 three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC)

Oral Presentation | June 1 (Mon), 11:45-11:57
Major Poster Presentations:
Lenvatinib
(Lenvima®)

Abstract No: 6013
Efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy

Poster Presentation | May 30 (Sat), 13:45-16:45 (Poster Discussion: 16:45-18:00)
Lenvatinib
(Lenvima®)

Abstract No: 6014
Pharmacodynamic biomarkers of outcomes and resistance in the phase 3 study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT)

Poster Presentation | May 30 (Sat), 13:45-16:45 (Poster Discussion: 16:45-18:00)
Lenvatinib
(Lenvima®)

Abstract No: 6048
Effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in SELECT

Poster Presentation | May 30 (Sat), 13:45-16:45

(Note) SELECT Study: Study of E7080 “LEnvatinib” in Differentiated Cancer of the Thyroid

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120